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2 ABSTRACT 
Although platinum-based chemotherapy remains as a standard treatment for advanced NSCLC 
patients, the clinical outcomes are poor and most patients develop high-grade toxicities. 
Genetic factors, such as single nucleotide polymorphisms (SNPs) involved in platinum 
pharmacodynamics, metabolism and mechanism of action, may account for inter-individual 
differences shown in effectiveness and toxicity. Polymorphisms in genes involved in DNA 
repair and others such as PI3K/PTEN/AKT and TGF-β pathways have been demonstrated to be 
associated with response, survival and toxicity in advanced NSCLC patients treated with 
platinum-based chemotherapy. Other cellular processes, like DNA methylation and 
proliferation have been connected with clinical outcome for platinum-based chemotherapy 
regimens through folate metabolism and cytokine signaling.  
The influence of gene polymorphisms in the NER pathway on clinical outcome has been 
extensively investigated in advanced NSCLC patients treated with platinum-based 
chemotherapy but contradictory results have been reported. The most recent and thorough 
meta-analyses have failed to show an association between ERCC1 C118T/C8092A and ERCC5 
rs1047768 polymorphisms and response to platinum based chemotherapy. However, other 
polymorphisms in ERCC2 (Lys751Gln and Asp312Asn) and ERCC5 (rs2094258 and rs2296147) 
and have been related with OS and PFS, respectively. The Arg194Trp and Gln399Arg 
polymorphisms in XRCC1, have also been extensively investigated. Their effects seem to be 
dependent on ethnicity, and recent meta-analyses have confirmed an association with 
response in Asian but not in Caucasian patients. The influence on ORR of the rs861539 
polymorphism in XRCC3, a protein of the DSB pathway, has also been confirmed in a meta-
analysis. 
Finally, SNPs in genes coding proteins of the p53, PI3K, TGF-β, membrane transporters, 
gluthatione metabolism enzymes and cytokine pathways have been less extensively 
investigated. Some polymorphisms have been reported to be associated with toxicity or 
clinical outcome, but data generally come from a limited number of studies and need to be 
confirmed. 
3 INTRODUCTION 
Lung cancer represents a serious health problem, being the leading cause of cancer mortality 
among both men and women worldwide, and is the second tumor in incidence (≈14%; only 
after prostate cancer in men and breast cancer in women) [1]. In the United States, over 
224390 new cases and 158080 deaths are estimated in 2015, according to the latest statistics 
published [1]. 
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the main types of lung 
cancer. NSCLC represents the great majority, with approximately 80% of all lung cancer cases, 
and is classified in different subtypes: squamous cell or epidermoid carcinoma, 
adenocarcinoma and large cell carcinoma. Most patients with NSCLC are diagnosed in an 
advanced stage (IIIB-IV, according to the American Joint Committee on Cancer) [2-4]. Five-year 
survival in this stage is poor, with rates of 5% for IIIB and 1% for IV stages [2-4]. 
The standard treatment for advanced or recurrent NSCLC wild-type for the epidermal growth 
factor (EGFR) gene and not harboring translocations in anaplastic lymphoma receptor tyrosine 
kinase (ALK) is platinum-based chemotherapy, usually in combination with anti-microtubule 
agents (taxanes and vinca alkaloids), antifolate agents (pemetrexed), or pyrimidine antagonist 
(gemcitabine). Although this therapy improves survival in comparison with best supportive 
care [5], response rates (RR) are less than 32%, progression-free survival (PFS) is around 3.5 
months and overall survival (OS) 7.4-11.3 months [6-9]. Furthermore, it is a very aggressive 
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treatment with severe side effects according to the Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4, such as neurotoxic effects (69.9%) or neutropenia (67.1%) [10]. 
Numerous studies have shown that platinum effectiveness and toxicity varies from person to 
person and that inter-individual differences may be due to genetic factors such as single 
nucleotide polymorphisms (SNPs) in particular genes [11-17]. 
Platinum drugs, particularly cisplatin and carboplatin, are heavy metal complexes that exert 
their antiproliferative effects by inducing DNA damage. They bind covalently to two different 
sites, either within the same DNA molecule or between two different DNA molecules, 
generating adducts  that inhibit DNA synthesis and transcription and are responsible for severe 
toxicity of these drugs [18,19]. Mammalian cells have different DNA repair pathways to repair 
DNA damage, including nucleotide-excision repair (NER), base excision repair (BER) and 
double-strand break repair (DSB) (Figure 1). Several proteins of these pathways, such as 
excision repair cross-complementing group 1 (ERCC1), excision repair cross-complementation 
group 2 (ERCC2, also known as XPD), excision repair cross-complementation group 5 (ERCC5), 
X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1) and X-ray 
repair complementing defective repair in Chinese hamster cells 3 (XRCC3), are involved in the 
detection and repair of the adducts and cross-links induced by platinum activity [20,21]. The 
p53 pathway also plays an essential role in DNA repair, together with cell cycle control and 
apoptosis initiation in response to DNA damage [22]. The MDM2 proto-oncogene, E3 ubiquitin 
protein ligase (MDM2)  modulates the activity of the pathway through directing binding, 
ubiquitination and degradation of p53 [23].  Numerous studies have reported that SNPs in any 
of these genes may regulate the DNA repair functions in the normal and tumor cells, 
contributing to individual variation in the response and toxicity to platinum-based 
chemotherapy [11-16,24-27]. 
Although DNA repair pathways are the key players in platinum toxicity and response, other 
pathways and proteins are also involved, including the phosphatase and phosphatidylinositol 
3-kinase / tensin homolog /v-akt murine thymoma viral oncogene (PI3K/PTEN/AKT) pathway, 
the transforming growth factor beta (TGF-β) and cytokine signaling pathways, drug 
transporters, detoxification systems and folate metabolism enzymes.  Genetic alterations in 
genes of the PI3K/PTEN/AKT and TGF-β pathways may modify signaling and have an impact in 
the development of toxicity or disease progression to platinum-based therapies [28-32]. 
Polymorphisms in ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1, also 
called MDR1) have also been suggested as predictive markers of response and side effects to 
platinum therapy [33-35].  ABCB1 gene is an cell membrane transporter [36], involved in the 
ATP dependent export of chemicals out of cell [37-39] that modulates response and toxicity by 
impairing the intracellular retention of multiple anticancer drugs [40,41]. Detoxification of 
platinum compounds is mediated by glutathione S-transferase Pi 1 (GSTP1); gene 
polymorphisms in this enzyme has been correlated with clinical outcome and toxicity of 
platinum therapy [42-49]. Methylenetetrahydrofolate reductase (MTHFR), methionine 
synthase (MTR) and solute carrier family 19 (folate transporter), members 1 (SLC19A1)  are 
involved in folate metabolism [50-54]. Genetic alterations in these genes disturb methylation 
of DNA, which may influence the effectiveness and toxicity of platinum-based chemotherapy 
[17,55-57]. Cytokine signaling regulates tumor progression by promoting angiogenesis, cell 
growth and differentiation of tumoral cells [58]. Finally, gene polymorphisms in interleukin 1B 
(IL1B), 6 (IL6), 12A (IL12A), 13 (IL13), 16 (IL16) have also been associated with survival to 
platinum-based chemotherapy [59,60]. 
In this review, we will discuss briefly the most relevant gene polymorphisms related with 
clinical outcomes and toxicity of platinum therapy in NSCLC patients. 
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4 DNA REPAIR PATHWAYS 
Genetic alterations in DNA repair genes can modify individual responses and toxic side effects 
to platinum-based chemotherapy. Four main DNA repair pathways are utilized by the cells:  
NER, BER, DBS and MMR (mismatch repair). NER, BER, and DBS are the main repair pathways 
in the removal of DNA lesions produced by platinum compounds [20,21]. MMR is not directly 
involved in repair of platinum adducts. It recognizes DNA adducts and activates apoptosis [61]. 
All of them are regulated by p53, which can trigger cell cycle arrest and DNA repair or 
apoptosis (Figure 1) [62-65]. 
4.1 NER PATHWAY 
The NER pathway, through ERCC1, ERCC2 and ERCC5 genes, is able to repair helix-distorting 
DNA lesions, which prevent base pairing, blocking transcription and normal replication [66-68].  
4.1.1 ERCC1 
ERCC1 is the key enzyme in the NER pathway [66]. It heterodimerizes with excision repair 
cross-complementation group 4 (ERCC4 also called XPF), and the resultant ERCC1/ERCC4 
complex makes an incision at the 5′ end of the lesion, allowing removal of the damaged DNA 
strand and further polymerization and religation [66,68].  
Two polymorphisms in ERCC1; rs11615 (C→T synonymous substitution at codon 118, exon 4, 
Asn→Asn, C118T) and rs3212986 (C→A substitution in the 3′-untranslated region, C8092A); 
have been extensively investigated in advanced NSCLC patients treated with platinum-based 
chemotherapy (Table 1) [44,49,69-88]. The possible mechanisms underlying the effects of 
these base changes in platinum therapy effectiveness and toxicity by is still unclear. Several 
studies have described some effects on ERCC1 mRNA expression, whereas others have found 
no association [89-91]. 
Regarding ERCC1 C118T, its association with clinical outcome to platinum-based chemotherapy 
remains unclear (Table 1) [13,24,44,49,69-88,92-100], with some studies reporting better 
overall response rate (ORR) in patients carrying the C allele [49,69-72], and others in patients 
with  the TT genotype [44,73-77]. Six meta-analyses have evaluated the influence of ERCC1 
C118T polymorphism [11-13,33,101,102] and the two largest (23 studies/3231 patients and 21 
studies/1281 patients, respectively), have not found any association between the ERCC1 
C118T polymorphism and ORR (OR=0.94; CI95%=0.72, 1.23; I2=60%; Pheterogeneity <0.01; CT/TT vs 
CC and OR=0.95; CI95%=0.85, 1.06; I2=66.90%; Pheterogeneity=0.386; CT/TT vs CC) [13,102]. The 
same contradictory results have been reported in the case of PFS and OS, with some studies 
finding an association of the CC genotype with a better outcome and others reaching opposite 
conclusions [13,49,70,72,75,77-84,96]. Finally, a meta-analysis including 13 studies, found a 
significant association of ERCC1 C118T polymorphism with a longer OS (OR=1.26; CI95%=1.02, 
1.55; I2=67%; Pheterogeneity<0.01; CT/TT vs CC) but not with PFS (OR=1.23; CI95%=0.90, 1.69; 
I2=70.7%; Pheterogeneity <0.01; CT/TT vs CC) [13]. 
The ERCC1 C8092A polymorphism has also been associated with response in two studies in 
115 and 163 Asian patients, which reported worse ORR to platinum-based chemotherapy in 
patients carrying the A allele (OR=0.23; CI95%=0.10, 0.57 for AC/AA vs CC and OR=0.44; 
CI95%=0.27, 0.74 for A vs C allele, respectively) [72,73]. Studies in Caucasian population have 
not found significant associations between ERCC1 C8092A polymorphism and outcome in 
advanced NSCLC patients [76,87,88,99] and four meta-analyses have reached the same 
conclusion; the largest one, a meta-analysis carried out with 10 studies and 1311 patients also 
failed to show influence of this polymorphism on response to platinum-based chemotherapy 
(OR=1.05; CI95%=0.83, 1.32; I2=39.3%; Pheterogeneity=0.096; AC/AA vs CC) [13]. Regarding OS and 
PFS, results for ERCC1 C8092A are again contradictory, with some reports associating the CC 
7 
 
genotype with better [72,77,80,85,86] and worse OS and PFS [87,88]. A recent meta-analysis, 
including 6 studies and 999 cases, could not find any significant association between the 
polymorphism and OS (HR=1.26; CI95%=0.81, 1.95; I2=87%; Pheterogeneity =<0.01; AC/AA vs CC) 
[13]. 
Finally, although the association between toxicity and ERCC1 polymorphisms has also been 
extensively investigated, no significant findings have been reported (Table 1) 
[49,76,79,87,88,91,103-111]. 
4.1.2 ERCC2 
The ERCC2 protein is a component of the general transcription factor IIH (TFIIH) and its 
helicase activity plays a key role gene transcription and nucleotide excision repair [67].  
Numerous SNPs in ERCC2 gene have been described, being rs13181 (A→C substitution at 
codon 751, exon 23, Lys→Gln) and rs1799793 (G→A substitution at codon 312, exon 10, 
Asp→Asp) the most investigated. Although both SNPs cause suboptimal DNA repair capacity 
[112,113], no significant association has been found between ERCC2 Lys751Gln or Asp312Asn 
and ORR or PFS (Table 2) [24,49,73,74,76,79,82,84,87,88,91-93,98,99,104,105,109,114-125]. 
This lack of association has been confirmed in two recent meta-analyses, including 22 
studies/3240 patients [13] and 12 studies/1737 patients [102]. In contrast, several studies 
have found an association between OS and both SNPs [49,98,118,120]. The genotype CC for 
ERCC2 Lys751Gln polymorphism has been correlated with a longer OS compared to the AC/AA 
genotypes in Asian population (HR=1.54; CI95%=1.03, 2.29; AC/AA vs CC) [118]. In the case of 
Asp312Asn, the AG/AA genotype has been associated with poor survival both in Caucasian and 
Asian populations (Table 2) [49,98,118,120]. A meta-analysis has also confirmed these results 
in Asian  (HR=2.07; CI95%=1.11, 3.88; AG/AA vs GG) but not in Caucasian population (HR=0.84; 
CI95%=0.62, 1.14; AG/AA vs GG) [13]. 
An relationship between ERCC2 Asp312Asn and Lys751Gln  and hematological toxicity has 
been reported in two small studies including 55 and 62 patients [79,107], with A-allele for 
ERCC2 Lys751Gln  associating with increased grade 2-3 neutropenia (p=0.04) [79] and the G-
allele Asp312Asn with a reduced frequency of severe hematological toxicity (OR=0.08; 
CI95%=0.01, 0.40; p=0.0005; AG/GG vs AA) [107].The AA genotype for  ERCC2 Lys751Gln  has 
also been associated with higher risk of severe nephrotoxicity (OR=0.07; CI95%=0.02, 0.31; 
AC/CC vs AA) [107]. Other studies in larger patient populations (65 to 493) failed to find such 
associations between ERCC2 polymorphisms and platinum-based chemotherapy toxicity (Table 
2) [49,76,87,88,91,104,105,109,110,117,118,124,126].  
Finally, three polymorphisms in ERCC2 (rs50872, rs238405, rs238416) have been correlated 
with clinical outcomes in a cohort 1290 Asian advanced NSCLC patients [127], with rs50872 
associated with longer OS (p=0.009) and PFS (p=0.032) in all patients, rs238405 in patients 
treated with a combination of platinum and taxanes and rs238416 in those receiving platinum 
and gemcitabine doublets [127]. 
4.1.3 ERCC5  
The ERCC5 gene encodes a single-strand specific DNA endonuclease, which cleaves the 
damaged DNA strand 3’ to the lesion during nucleotide excision repair [128]. 
The TT genotype in the ERCC5 rs1047768 polymorphism (T→C substitution at codon 46, exon 
2, His→His) has been associated with increased ORR (OR=1.90; CI95%=1.10, 3.28; TT vs CC), OS 
(HR=0.52; CI95%=0.31, 0.96; TT vs CC) and PFS (HR=0.47; CI95%=0.22, 0.82; TT vs CC) [129]. A 
meta-analysis which included 5 studies with 846 cases, has recently confirmed these results for 
ORR (RR=1.23; CI95%=1.11, 1.36 I2=0%; Pheterogeneity=0.480; CT/TT vs CC) [102] while no 
association of rs1047768 with toxicity was found in 74 Spanish NSCLC patients [76]. In 
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contrast, ERCC5 rs17655 polymorphism (G→C substitution at codon 1104, exon 15, Asp→His) 
has been related with a higher infection rate (p=0.017) in 388 Chinese NSCLC patients [130] 
but not with  clinical outcome (Table 3) [76,84,93,131-133].  
Three additional polymorphisms in ERCC5 (rs2094258, rs2296147, rs873601) have also been 
investigated. The G-allele for ERCC5 rs2094258 has been associated with increased OS 
(HR=0.51; CI95%=0.39, 0.82; AG/GG vs AA) and PFS (HR=0.44; CI95%=0.34, 0.78; AG/GG vs AA) in 
433 advanced NSCLC patients treated with platinum-based chemotherapy [133]. In the case of 
ERCC5 rs2296147, two studies in 433 and 277 Chinese patients found a significant association 
with OS (HR=0.66; CI95%=0.48, 0.99 for CT/TT vs CC and HR=0.49; CI95%=0.36, 0.68 for T vs C 
allele) and PFS (HR=0.73; CI95%=0.51, 0.97 for CT/TT vs CC and HR=0.52; CI95%=0.38, 0.70 for T 
vs C allele) [131,133]. Finally, the allele G of the rs873601 polymorphism correlated with a 
better OS (HR=0.84; CI95%=0.64, 1.09; G vs A allele) in 277 Chinese stage III/IV NSCLC patients 
[131]. 
4.2 BER PATHWAY 
The BER pathway removes small, non-helix-distorting base lesions from the genome, including 
single strand breaks produced by oxidation, methylation, deamination and hydroxylation 
[134]. These lesions may not block transcription and normal replication, but they usually cause 
miscoding. In this process, the enzymes poly (ADP ribose) polymerase 1 and 2 (PARP1 and 
PARP2) play a key role, along with apurinic/apyimidinic endonuclease 1 (APE1) and XRCC1 
[135,136].  
4.2.1 XRCC1 
The XRCC1 protein interacts with DNA polymerase-beta, DNA ligase III and PARP (poly ADP-
ribose polymerase), repairing the damaged DNA strand [137].  
XRCC1 rs1799782 (A→G substitution at codon 194, exon 6, Arg→Trp) and rs25487 (A→G 
substitution at codon 399, exon 10, Gln→Arg) polymorphisms are the most studied. The T-
allele for XRCC1 Arg194Trp has been associated with better ORR in Asian population, but not in 
Caucasian patients (Table 4) [76,107,132,138-141]. A recent meta-analysis, which involved 11 
studies and compiled 1329 cases, has reported similar results in Asian population (OR=0.38; 
CI95%=0.30, 0.48; I2=0%; Pheterogeneity=0.830; CT/TT vs CC) [15]. For XRCC1 Gln399Arg, several 
studies in Asian population have found a relationship between genotype GG and higher ORR 
(Table 4) [47,97,140,142]. This result has been confirmed by a recent meta-analysis, which 
evaluated 13 studies and 1334 cases from Asian population (OR=2.05; CI95%=1.62, 2.60; I2=26%; 
Pheterogeneity=0.18; GG vs AG/AA) [15]. However, more recent studies in 325 and 147 Chinese 
patients have reported poor ORR for GG genotype [43,143]. No significant association has 
been reported in Caucasian population (Table 4) [49,76,87,88,99,121].  
The XRCC1 Gln399Arg polymorphism has also been associated with OS, PFS and toxicity 
[42,43,47,99,107,144]. A longer OS for the AA genotype has been reported in two studies in 
Asian (OR=1.69; CI95%=1.19, 2.39 for GG vs AG/AA and OR=0.17; CI95%=0.06, 0.41 for AA vs GG) 
and one in Caucasian populations (OR=0.47; CI95%=0.23, 0.95 for A vs G allele) [43,99,144]. The 
GG genotype showed significant results for PFS in 114 stage-IV NSCLC patients (OR=1.768; 
CI95%=1.14, 2.73 for AG/AA vs GG) [47] and has also been linked with increased hematological 
(OR=0.323; CI95%=0.121, 0.862 for AG/AA vs GG and OR=0.22; CI95%=0.06, 0.82 for AG/AA vs 
GG) and gastrointestinal toxicity (OR=0.298; CI95%=0.108, 0.825 for AG/AA vs GG) [42,107,144]. 
In contrast, other study reported higher incidence of hematological toxicity for AA/AG 
genotype (OR=2.135; CI95%=1.207, 3.777 for AG/AA vs GG) [144]. Finally, no associations 
between OS, PFS, toxicity and XRCC1 Arg194Trp SNPs have been found (Table 4) 
[43,76,107,119,129,143,145,146].  
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4.2.2 PARP1, PARP2 and APE1 
The role of PARP1, PARP2 and APE1 polymorphisms on clinical outcomes to cisplatin in 
advanced NSCLC has been less investigated. The T-allele for APE1 rs1760944 polymorphism 
was found to be associated with gastrointestinal toxicity in 235 patients [144], and the GG 
genotype for APE1 rs3136820 showed better OS compared to the TT genotype in 147 patients 
(HR=0.33; CI95%=0.12, 0.92) [143]. A polymorphism in PARP1 (rs1136410) has also been 
associated with survival; in particular, patients with CC genotype showed lower PFS than CT/TT 
patients (HR=1.90; CI95%=1.02-3.52) [143]. Finally, no studies have evaluated polymorphisms in 
PARP2 and their associations with clinical outcomes or toxicity. 
4.3 DSB PATHWAY 
The DSB pathway is involved in repairing the most severe lesions, affecting both strands, which 
may result in cell death or a diversity of genetic alterations, such as deletions and 
chromosomal aberrations [147]. Homologous recombination (HR) and non-homologous end-
joining (NHEJ) are the two main mechanisms  of the DSB pathway [147]. Key proteins involved 
are MRE11 (MRE11 homolog A, double strand break repair nuclease), NBN (nibrin) and RAD50 
(RAD50 double strand break repair protein), which form the MRE11 complex, BRCA1 (breast 
cancer 1), BRCA2 (breast cancer 2), RAD51 (RAD51 recombinase) and XRCC3 [147,148]. Despite 
of the essential function of these proteins in DSB pathway, only a polymorphism in XRCC3 gene 
has been extensively studied [49,84,92,98,99,105,106,110,117,149-152]. 
The C→T substitution at codon 241, exon 7 of XRCC3 (Thr→Met, rs861539) has been 
associated with ORR and OS, but not with PFS or toxicity (Table 5) 
[49,84,98,99,105,106,110,117,149-152] The genotype CT/TT has shown higher ORR (OR=2.72; 
CI95%=1.17, 6.31 for CT/TT vs CC) in 137 Caucasian stage III-IV NSCLC patients [49], a result 
confirmed by a meta-analysis that included 7 studies and 1186 patients  (OR=1.51; CI95%=1.10, 
2.07; I2=0%; Pheterogeneity=0.618; CT/TT vs CC) [16]. The TT genotype has also been associated 
with prolonged OS in 135 Caucasian stage III-IV NSCLC patients (OR=0.43; CI95%=0.22, 0.82 for 
TT vs CC) [92]. 
5 p53 PATHWAY 
The TP53 tumor suppressor gene regulates the  DNA repair through its ability to act as a 
transcription factor and to interact with damaged DNA, promoting the activation of DNA repair 
mechanisms [153,154]. In addition, TP53 may induce apoptosis, arresting the cell cycle 
progression, when DNA damage is extensive [155,156] (Figure 1). 
5.1 TP53 
The TP53 tumor suppressor gene has a prominent role in carcinogenesis [156]. It has an anti-
cancer function, inhibiting angiogenesis, inducing apoptosis of tumor cells and maintaining 
genomic stability [156]. This gene is frequently somatically mutated in NSCLC (40-70%), which 
may modify p53 activity and induce resistance to platinum based chemotherapy [157].  
In tumor cell lines with a wild type TP53 gene, the GG genotype of a common TP53 
polymorphism located at codon 72, exon 4 (C→G, rs1042522, Pro72Arg), enhances the risk of 
death by promoting the mitochondrial localization of p53 [158]. When the p53 protein is 
mutated, the polymorphism has the opposite effect [159,160]. In NSCLC patients treated with 
platinum compounds, the p53 mutant protein with GG genotype has been described to abolish 
the function of p73, a related p53 protein, and therefore inhibit apoptosis [24]. The CC 
genotype has shown better response (OR=3.02; CI95%=1.77, 5.18; CC vs GG) in 640 NSCLC 
patients treated with platinum compounds [24] while the GG variant has been associated with 
higher gastrointestinal toxicity (OR=0.24; CI95%=0.076, 0.810 for GC/CC vs GG) (Table 6) [25].  
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5.2 MDM2 
The MDM2 protein is a negative regulator of p53 that binds to the p53 protein inducing its 
ubiquitination and degradation [23]. Two polymorphisms in MDM2 (C→T, rs1470383 and 
A→G, rs1690924) have been associated with gastrointestinal and hematological toxicity, but 
not with OS and PFS in 663 Chinese NSCLC patients (Table 6) [27]. Patients with the AA 
genotype for MDM2-rs1470383 showed lower hematological chemotherapy-related toxicity 
than those with the GG genotype (OR=4.10; CI95%=1.73, 9.71 for GG vs AA) [27]. In contrast, the 
GG genotype for MDM2 rs1690924 has been related to lower gastrointestinal toxicity 
(OR=2.32; CI95%=1.30, 4.14 for AG vs AA) (Table 6) [27]. The relationship between these SNPs 
with response has not been evaluated. 
An association has also been found between a SNP in the promoter region of MDM2 (T→G, 
rs2279744) and clinical outcomes in NSCLC patients treated with cisplatin/carboplatin [25,26]. 
The GG genotype correlated with longer OS (HR=1.33; CI95%=1.03, 1.72 for GT/TT vs GG) in 568 
NSCLC patients [26] and lower hematological toxicity in 444 Chinese advanced NSCLC patients 
(OR=2.18; CI95%=1.12, 4.25 for GT/TT vs GG) [25]. 
6 PI3K/PTEN/AKT PATHWAY 
The PTEN/PI3K/AKT signaling is involved in a great variety of cell processes, such as cell 
proliferation and survival, which may be altered by polymorphisms in the genes that integrate 
the pathway [161].  
6.1 PI3K 
The PI3K enzyme catalyzes the conversion of PIP2 into PIP3, activating the downstream AKT 
signaling [162]. Despite of this key role, none of the polymorphisms studied to date in the PI3K 
gene (A→G, rs7651265; C→G, rs7640662; T→C, rs7621329, A→C rs6443624; G→A, rs2699887) 
have shown a significant association with clinical outcomes in NSCLC patients treated with 
platinum based chemotherapy [28]. Only the AA genotype for rs2699887 has been correlated 
with increased grade 3-4 toxicity in 168 Caucasian stage IIIB/IV NSCLC patients (OR=3.86; 
CI95%=1.08, 13.82 for GG vs AA) [28].  
6.2 PTEN 
PTEN, a well-known tumor suppressor gene, codifies a protein phosphatase  that hydrolyzes 
PIP3 and inhibits the PTEN/PI3K/AKT pathway [163,164].Three polymorphisms in PTEN 
(T→A/C, rs2299939; T→G rs12569398, G→C rs12557281) have been evaluated, and only the 
AA genotype in rs2299939  has been associated with severe toxicity in 168 Caucasian stage 
IIIB/IV NSCLC patients (OR=0.44; CI95%=0.20, 0.95 for AC/CC vs AA) [28]. The influence of these 
SNPs on ORR, PFS and OS has not been determined.  
6.3 AKT 
The AKT protein is the main downstream target of PI3K pathway. It triggers the 
phosphorylation of a series of intermediates effectors, promoting cell cycle progression, cell 
proliferation, transcription and cell migration [165-167]. 
The T allele in the AKT polymorphisms rs3803304 and rs2498804 have been associated with  
longer PFS in advanced NSCLC patients treated with cisplatin-based chemotherapy (HR=0.66; 
CI95%=0.45, 0.97 for CT/TT vs CC and HR=0.52; CI95%=0.35, 0.77 for GT/TT vs GG, respectively) 
[28]. In contrast, the GG genotype of AKT rs1130214 have been correlated with  shorter PFS in 
168 advanced NSCLC patients (HR=0.62; CI95%=0.42, 0.91 for GT/TT vs GG) [28], while it was 
associated with better OS (HR=2.78; CI95%=1.11, 6.99 for TT vs GG) and PFS (HR=1.48; 
CI95%=1.02, 2.15 for TT vs GG) in 310 early NSCLC patients receiving cisplatin-based adjuvant 
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therapy [168]. No association with toxicity has been described in any polymorphism, and ORR 
has not been evaluated [28]. 
7 TGF-β PATHWAY 
The TGF-β pathway regulates tumorigenesis and tumor progression through its effects on 
cellular proliferation, survival, angiogenesis and invasion, via cross talk with SMAD 
transcriptional regulators [32].  
The CT/TT genotypes for the SMAD3 polymorphisms rs6494633 and rs11632964 have been 
associated with better OS (HR=1.20; CI95%=1.01, 1.43 for CC vs CT/TT and HR=1.52; CI95%=1.05, 
2.17 for CC vs CT/TT, respectively) in 598 Caucasian stage IIIA/IV NSCLC patients [29]. In 
contrast, polymorphisms in TGF-β receptor  do not seem to be associated with response and 
survival to platinum based chemotherapy [29]. 
8 CELLULAR EFFLUX TRANSPORTERS 
Proteins involved in drug efflux are responsible of extruding drugs out of the cell [36,40,41] 
and polymorphisms in the corresponding genes have been associated with efficacy of platinum 
based chemotherapy in advanced NSCLC. 
8.1 ABCB1 
ABCB1 is the most extensively studied transmembrane cellular efflux transporter. It belongs to 
the ATP-binding cassette family, and pumps out the cell an enormous variety of drugs, 
including platinum compounds [36,40,41]. Polymorphisms in this gene lead to lower 
expression and activity of ABCB1 protein, increasing levels of drugs outside the cells [169]. 
Contradictory results have been obtained when analyzing the association of the silent 
polymorphism rs1045642,  (C→T substitution at codon 1142, exon 26, position 3435, C3435T)  
[169], with ORR to platinum drugs in advanced NSCLC (Table 7) [74,79,103,109,170-172]. 
Although a meta-analysis, including 5 studies with a total of 379 Asian and Caucasian patients,  
reported higher ORR for the CC variant (OR=1.82; CI95%=1.17, 2.85; I2=0%; Pheterogeneity=0.77; CC 
vs CT/TT) [33]. The C-allele has also been associated with better OS (HR=0.77; CI95%=1.11, 6.99 
for C vs T allele) and PFS (HR=0.62; CI95%=0.38, 1.00 for C vs T allele) in two studies including 
160 and 94 advanced NSCLC patients, respectively [34,109]. A correlation with grade 3-4 
gastrointestinal toxicity was also initially reported in 62 stage IIIB-IV NSCLC patients (p=0.03) 
[79], but in further studies failed to confirm it [35,103,109]. 
A meta-analysis in Asian population, with a total of 3 studies and 96 patients, has reported 
better ORR for the GG variant (OR=2.61; CI95%=1.44, 4.74; I2=0%; Pheterogeneity=0.51; GG vs 
GT/GA/TT/AA) of a polymorphism in linkage disequilibrium with C3435T SNP (Ala893Ser, 
rs2032582), which  modifies the expression of the ABCB1 protein [33,103]. In contrast, no 
significant association with toxicity was reported and PFS and OS were not evaluated (Table 7) 
[103]. 
Finally, contradictory reports have also been published regarding the silent SNP rs1128503 
(Gly412Gly) The C-allele was associated with longer OS (HR=1.53; CI95%=1.11, 2.09 for C vs T 
allele) and PFS (HR=2.04; CI95%=1.11, 3.77 for C vs T allele) in 160 stage III-IV NSCLC patients 
[34] while an analysis of 86 stage IIIB-IV NSCLC patients reported shorter PFS for CC genotype 
(HR=0.541; CI95%=-1.112, -0.117 for CT/TT vs CC) in [35]. No association with toxicity was found 
and ORR was not studied. 
9 GLUTHATHIONE METABOLIC PATHWAY 
The glutathione metabolic pathway mediates platinum detoxification through glutathione 
conjugation [173]. Glutathione S-transferase (GSTPs) enzymes catalyze this process. The major 
subclasses of GSTs are GSTM1, GSTP1, GSTT1, and GSTA1 [174]; being GSTP1 the most 
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abundant isoform in the lung and the enzyme mainly involved in platinum detoxification in 
NSCLC patients [175,176]. A single nucleotide substitution at exon 5 (G→A, rs1695, Ile105Val) 
has been demonstrated to alter GSTP1 activity [177], with the Val variant being more active 
against cisplatin and carboplatin compounds [47,49,178]. Several studies have reported that 
the AG/GG genotypes in rs1695 are associated with better ORR, PFS and OS (Table 8) [42-47] 
and that the GG genotype correlates with less severe hematological toxicity (p=0.02), but 
higher neurotoxicity (p=0.01) [48,49]. 
10 FOLATE METABOLISM 
Folate metabolisms is involved in various intracellular processes such as DNA methylation, cell 
proliferation and synthesis of nucleic and amino acids [179]. Genetic alterations in these genes 
may disrupt folate metabolism function, inducing DNA hypomethylation and consequently 
activating proto-oncogenes [180-184]. Thus, polymorphisms in folate metabolism genes may 
promote tumor development and modify sensitivity of tumor cells to platinum compounds. 
10.1 MTHFR 
MTHFR is a crucial enzyme in the folate metabolism. Several polymorphisms in this gene lead 
to a production of an enzyme with decreased activity and their effects have been linked with 
DNA hypomethylation, therefore influencing platinum therapy outcomes [180-184].  
A C→T transition at codon 222, exon 4 (Val→Ala, rs1801133) has been found to be associated 
with response, survival and toxicity of platinum compounds drugs. A meta-analysis compiling 
data from 3 studies and 147 patients, both in Asian and Caucasian populations, has shown 
better response in individuals with TT genotype (OR=1.72; CI95%=1.01, 2.93; I2=16%; 
Pheterogeneity=0.31; TT vs CT/CC) [17]. The TT variant has also been associated with higher OS 
(p=0.026) and PFS (p=0.012) in 208 Italian stage IIIB/IV NSCLC patients (Table 9) [122]. 
Likewise, the genotype CC has been correlated with higher hematological toxicity in 1004 
Chinese stage III/IV NSCLC patients (OR=0.40; CI95%=0.19, 0.85 for CT vs CC) (Table 9) [185].  
Another polymorphism in MTHFR, which results in an A→C substitution at codon 429, exon 7 
(Glu→Ala, rs1801131), has also been associated to platinum based chemotherapy outcomes 
[185]. Carriers of AA genotype presented lower ORR (OR=1.52; CI95%=1.04, 2.23 for AC vs AA), 
PFS (p=0.03) and higher gastrointestinal toxicity in a study conducted in 1004 Chinese stage 
III/IV NSCLC patients (OR=0.40; CI95%=0.22, 2.23 for AC vs AA) (Table 9) [185].  
10.2 MTR 
MTR is an important vitamin B12-dependent enzyme, which catalyzes the final step in folate 
metabolism [50].   
A transition from A to G at position 2756, exon 26 (rs1805087) causes an amino acid change of 
Asp to Gly, which has been reported to modify enzyme activity and alter DNA methylation 
processes [186,187]. However, no significant was found with ORR (OR=0.66; CI95%=0.23, 1.89 
for AG/GG vs AA) and OS (HR=0.99; CI95%=0.23, 1.89 for AG/GG vs AA) in two studies including 
465 I-IV and 101 IIIB/IV NSCLC patients treated with platinum based chemotherapy (Table 9)  
[56,57].  
10.3 SLC19A1 
The reduced folate carrier SLC19A1 is responsible for the transport of folate drugs into the cell, 
such as pemetrexed, a drug that is usually given in combination with carboplatin/cisplatin 
[188]. Polymorphisms in this gene may modify the passage of this drug into the tumor cell. 
A single nucleotide transition (G→A, rs1051266) at exon 2, which induces an Arg→His 
replacement in codon 27, has demonstrated to alter pemetrexed-platinum combination 
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efficacy [55]. The GG genotype has been associated with better OS (HR=1.76; CI95%=1.11, 2.78 
for AG/AA vs GG) in 136 lung cancer patients (Table 9)  [55]. However, no significant 
associations have been reported for ORR, PFS and toxicity (Table 9) [55,122,189-191].  
11 CYTOKINE SIGNALING 
The innate immune cells induce inflammation as a physiological process aimed to combat 
infection. However, chronic inflammation may cause persistent tissue damage and cellular 
proliferation leading to metaplasia and dysplasia [192,193]. Consequently, there are 
prominent connections between chronic inflammation, infection and early stage of neoplastic 
development. Clinical and epidemiological studies have reported that 20% of tumors are 
associated to chronic infection, 30% associated to tobacco smoking and pollutant inhalation 
and 35% are related to nutrition [194]. 
Growth, differentiation, and activation of immune cells are mediated by a family of cytokines 
referred as interleukins (ILs) [195]. During tumor development, ILs act as autocrine and 
paracrine growth factors, inhibiting apoptosis at the site of inflammation [58]. IL 
polymorphisms have recently been associated with OS in stage IIIB-IV NSCLC patients receiving 
platinum based chemotherapy. In the case of the IL1B rs1143634 polymorphism, the T-allele 
has been correlated with better OS (HR=0.78; 95%CI=0.63, 0.98 for CT/TT vs CC) and PFS 
(HR=0.73; CI95%=0.57, 0.93 for CT/TT vs CC) in 651 Caucasian patients [60]. Likewise, the CC 
genotype for IL6 rs1800795 was found to be associated with better OS (HR=1.682; CI95%=1.077, 
2.628 for CG/GG vs CC) in 414 Portuguese stage I-IV NSCLC patients [59]. Finally, the CT/TT 
genotypes for IL12A (rs662959) (HR=1.41; CI95%=1.08, 1.83 for CT/TT vs CC), AC/CC for IL13 
(rs1881457) (HR=1.29; CI95%=1.00, 1.66 for AC/CC vs AA) and GG for IL16 (rs7170924) 
(HR=0.65; CI95%=0.50, 0.83 for GT/TT vs GG) have been associated with lower PFS in 651 
Caucasian stage I-IV NSCLC patients [60]. 
12 CONCLUSIONS 
The influence of gene polymorphisms in the NER pathway on clinical outcome has been 
extensively investigated in advanced NSCLC patients treated with platinum-based 
chemotherapy but contradictory results have been reported. The most recent and thorough 
meta-analyses have failed to show an association between ERCC1 C118T/C8092A and ERCC5 
rs1047768 polymorphisms and response to platinum based chemotherapy. However, other 
polymorphisms in ERCC2 (Lys751Gln and Asp312Asn) and ERCC5 (rs2094258 and rs2296147) 
and have been related with OS and PFS, respectively. 
The Arg194Trp and Gln399Arg polymorphisms in XRCC1, a protein of the BER pathway, have 
also been extensively investigated. Their effects seem to be dependent on ethnicity, and 
recent meta-analyses have confirmed an association with response in Asian but not in 
Caucasian patients. The influence on ORR of the rs861539 polymorphism in XRCC3, a protein 
of the DSB pathway, has also been confirmed in a meta-analysis. 
Finally, SNPs in genes coding proteins of the p53, PI3K, TGF-β, membrane transporters, 
gluthatione metabolism enzymes and cytokine pathways have been less extensively 
investigated. Some polymorphisms have been reported to be associated with toxicity or 
clinical outcome, but data generally come from a limited number of studies and need to be 
confirmed. 
In summary, we suggested that those polymorphisms in genes most extensively studied such 
as ERCC2, XRCC1 and XRCC3 may be used in the future as a prognostic and predictive 
biomarkers informing patient care. ERCC1 C118T/C8092A gene polymorphisms may also be 
used in clinical practice after clarifying the conflicting results that may be based on the 
heterogeneity of the population. Polymorphisms in genes belonging to TP53, PI3K, TGF-β 
pathways, membrane transporters, gluthatione metabolism enzymes and cytokine pathways 
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have showed an influence on clinical outcomes of NSCLC patients treated with platinum-based 
chemotherapy but the sample size is insufficient to confirm its effect on clinical outcomes of 
platinum-based chemotherapy. Thus, further examination involving a large homogeneous 
sample size (stratified by gender, age and smoking status) and longer follow up is required for 
these polymorphisms.  
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Graphical Abstract 
Figure 1. DNA repair pathways involved in removal DNA lesions produced by platinum 
compounds. 
